Literature DB >> 12211263

Pharmacogenetics: ethical issues and policy options.

Allen Buchanan1, Andrea Califano, Jeffrey Kahn, Elizabeth McPherson, John Robertson, Baruch Brody.   

Abstract

Pharmacogenetics offers the prospect of an era of safer and more effective drugs, as well as more individualized use of drug therapies. Before the benefits of pharmacogenetics can be realized, the ethical issues that arise in research and clinical application of pharmacogenetic technologies must be addressed. The ethical issues raised by pharmacogenetics can be addressed under six headings: (1) regulatory oversight, (2) confidentiality and privacy, (3) informed consent, (4) availability of drugs, (5) access, and (6) clinicians' changing responsibilities in the era of pharmacogenetic medicine. We analyze each of these categories of ethical issues and provide policy approaches for addressing them.

Keywords:  Biomedical and Behavioral Research; Genetics and Reproduction

Mesh:

Year:  2002        PMID: 12211263     DOI: 10.1353/ken.2002.0001

Source DB:  PubMed          Journal:  Kennedy Inst Ethics J        ISSN: 1054-6863


  12 in total

Review 1.  Pharmacogenetics and psychiatry.

Authors:  Amlan Basu; Eva Tsapakis; Kathy Aitchison
Journal:  Curr Psychiatry Rep       Date:  2004-04       Impact factor: 5.285

2.  Delivering a pharmacogenetic service: is there a role for genetic counselors?

Authors:  Alice Callard; William Newman; Katherine Payne
Journal:  J Genet Couns       Date:  2011-11-04       Impact factor: 2.537

3.  Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report.

Authors:  O P Corrigan
Journal:  J Med Ethics       Date:  2005-03       Impact factor: 2.903

Review 4.  A review of consent practices and perspectives for pharmacogenetic testing.

Authors:  Susanne B Haga; Rachel Mills
Journal:  Pharmacogenomics       Date:  2016-08-17       Impact factor: 2.533

Review 5.  Within and beyond the communal turn to informed consent in industry-sponsored pharmacogenetics research: merits and challenges of community advisory boards.

Authors:  Hojjat Soofi; Evert van Leeuwen
Journal:  J Community Genet       Date:  2016-08-05

6.  Why personalized medicine will fail if we stay the course.

Authors:  Edward Ramos; Shawneequa L Callier; Charles N Rotimi
Journal:  Per Med       Date:  2012-11       Impact factor: 2.512

Review 7.  Attitudes of health care professionals toward pharmacogenetic testing.

Authors:  Nathalie K Zgheib; Thalia Arawi; Rami A Mahfouz; Ramzi Sabra
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

Review 8.  Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.

Authors:  Katherine I Morley; Wayne D Hall
Journal:  J Mol Med (Berl)       Date:  2003-11-04       Impact factor: 4.599

9.  Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions.

Authors:  Susanne B Haga; Julianne M O'Daniel; Genevieve M Tindall; Isaac R Lipkus; Robert Agans
Journal:  Genet Med       Date:  2011-08       Impact factor: 8.822

10.  Ethical concerns related to developing pharmacogenomic treatment strategies for addiction.

Authors:  Alexandra E Shields
Journal:  Addict Sci Clin Pract       Date:  2011-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.